Skip to content
Screener

Gyre Therapeutics, Inc. GYRE SG&A

SG&A at other companies

Eli Lilly logo
Eli LillyLLY
$3.43B+24.6%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$289.38M+47.0%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$14.18M-23.1%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$30.65M+10.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$16.56M-20.3%
LQD
Liquidia CorporationLQDA
$57.43M+47.9%

Segments

By segment

See full
Gyre Pharmaceuticals$4.27M+49.3%
Gyre$3.59M-18.6%

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$712.55M+11.2%
Enterprise value$672.68M+11.0%
P/S6×-0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp
FCF margin-5.1%—

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0×0.0×
Current ratio4.3×-1.1×

FAQ

What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.